Journal ArticleDOI
Regulatory Roles of the N-Terminal Domain Based on Crystal Structures of Human Pyruvate Dehydrogenase Kinase 2 Containing Physiological and Synthetic Ligands†,‡
Thorsten R. Knoechel,Alec D. Tucker,Colin M. Pfizer Global Res. Dev. Robinson,Chris Phillips,Wendy E. Pfizer Global Res. Dev. Taylor,Peter J. Bungay,Shane A. Kasten,Thomas E. Roche,David Graham Brown +8 more
TLDR
It is concluded that the N-terminal domain of PDHK has a key regulatory function and proposed that the different inhibitor classes act by discrete mechanisms.Abstract:
Pyruvate dehydrogenase kinase (PDHK) regulates the activity of the pyruvate dehydrogenase multienzyme complex. PDHK inhibition provides a route for therapeutic intervention in diabetes and cardiovascular disorders. We report crystal structures of human PDHK isozyme 2 complexed with physiological and synthetic ligands. Several of the PDHK2 structures disclosed have C-terminal cross arms that span a large trough region between the N-terminal regulatory (R) domains of the PDHK2 dimers. The structures containing bound ATP and ADP demonstrate variation in the conformation of the active site lid, residues 316−321, which enclose the nucleotide β and γ phosphates at the active site in the C-terminal catalytic domain. We have identified three novel ligand binding sites located in the R domain of PDHK2. Dichloroacetate (DCA) binds at the pyruvate binding site in the center of the R domain, which together with ADP, induces significant changes at the active site. Nov3r and AZ12 inhibitors bind at the lipoamide bindin...read more
Citations
More filters
Journal ArticleDOI
A Mitochondria-K+ Channel Axis Is Suppressed in Cancer and Its Normalization Promotes Apoptosis and Inhibits Cancer Growth
Sébastien Bonnet,Stephen L. Archer,Joan Allalunis-Turner,Alois Haromy,Christian Beaulieu,Richard B. Thompson,Christopher T. Lee,Gary D. Lopaschuk,Lakshmi Puttagunta,Sandra Bonnet,Gwyneth Harry,Kyoko Hashimoto,Christopher J. Porter,Miguel A. Andrade,Bernard Thébaud,Evangelos D. Michelakis +15 more
TL;DR: The unique metabolic profile of cancer (aerobic glycolysis) might confer apoptosis resistance and be therapeutically targeted and the orally available DCA is a promising selective anticancer agent.
Journal ArticleDOI
The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism
TL;DR: The findings reveal mitochondrial oxidative metabolism as a critical suppressor of metastasis and justify metabolic therapies for potential prevention/intervention of tumor metastasis.
Journal ArticleDOI
Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review
TL;DR: This review addresses in a comprehensive manner the main molecular events accounting for high-rate glycolysis in cancer, and highlights the key role exerted by the hypoxia-inducible transcription factor HIF-1 in long-term adaptation to Hypoxia.
Journal ArticleDOI
The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle
Lin Piao,Yong Hu Fang,Virgilio J. J. Cadete,Christian Wietholt,Dalia Urboniene,Peter T. Toth,Glenn Marsboom,Hannah J. Zhang,Idith Haber,Jalees Rehman,Gary D. Lopaschuk,Stephen L. Archer +11 more
TL;DR: Reduction in RV function and electrical remodeling in two models of RVH relevant to human disease (PAH and pulmonic stenosis) result, in part, from a PDK-mediated glycolytic shift in the RV.
Journal ArticleDOI
Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer
Thomas E. Roche,Yasuaki Hiromasa +1 more
TL;DR: Activation of PDC by synthetic PDK inhibitors binding at the pyruvate or lipoyl binding sites decreased damage during heart ischemia and lowered blood glucose in insulin-resistant animals and triggers apoptosis in cancer cells that selectively convert glucose to lactate.
References
More filters
Journal ArticleDOI
Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone
Chrisostomos Prodromou,S. Mark Roe,Ronan O'Brien,John E. Ladbury,Peter W. Piper,Laurence H. Pearl +5 more
TL;DR: Crystal structures of complexes between the N-terminal domain of the yeast Hsp90 chaperone and ADP/ATP unambiguously identify a specific adenine nucleotide binding site homologous to the ATP-binding site of DNA gyrase B, suggesting that geldanamycin acts by blocking the binding of nucleotides to Hsp 90 and not the binding to incompletely folded client polypeptides as previously suggested.
Journal ArticleDOI
Methods used in the structure determination of bovine mitochondrial F1 ATPase.
TL;DR: The F(1) ATPase particle is the largest asymmetric structure solved to date and the most important feature is that the electron density in the solvent region is inverted rather than set to a constant value, as in conventional solvent flattening.
Journal ArticleDOI
GHKL, an emergent ATPase/kinase superfamily.
Rinku Dutta,Masayori Inouye +1 more
TL;DR: A novel ATP-binding superfamily that includes diverse protein families such as DNA topoisomerase II, molecular chaperones Hsp90, DNA-mismatch-repair enzymes MutL and histidine kinases is recognition.
Journal ArticleDOI
In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis
Wolfgang M.J. Obermann,Holger Sondermann,Alicia A. Russo,Nikola P. Pavletich,F. Ulrich Hartl +4 more
TL;DR: It is shown that both ATP binding and hydrolysis are required for Hsp82 function in vivo, and the results establish Hsp90 as an ATP-dependent chaperone.
Journal ArticleDOI
Molecular biology and biochemistry of pyruvate dehydrogenase complexes.
TL;DR: A combination of biochemical and molecular biology studies have greatly expanded the understanding of the overall structural organization of this multicomponent system, delineated the locations and elucidated the functions of structural domains of the catalytic components, and revealed significant evolutionary changes.